SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-052342
Filing Date
2022-02-24
Accepted
2022-02-24 17:05:00
Documents
15
Period of Report
2022-02-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d313645d8k.htm   iXBRL 8-K 31578
2 EX-5.1 d313645dex51.htm EX-5.1 9747
3 EX-10.1 d313645dex101.htm EX-10.1 242934
7 GRAPHIC g313645dsp123456.jpg GRAPHIC 8033
  Complete submission text file 0001193125-22-052342.txt   480023

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA kura-20220224.xsd EX-101.SCH 2872
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE kura-20220224_lab.xml EX-101.LAB 17995
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kura-20220224_pre.xml EX-101.PRE 11272
9 EXTRACTED XBRL INSTANCE DOCUMENT d313645d8k_htm.xml XML 3353
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

IRS No.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37620 | Film No.: 22672217
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences